Plant Name: Hesperocyparis goveniana var. abramsiana
Taxonomic Information:
Plant ID: NPO14163.1
Plant Latin Name: Hesperocyparis goveniana var. abramsiana
Taxonomy Genus: Hesperocyparis
Taxonomy Family: Cupressaceae
Plant External Links:
NCBI TaxonomyDB:
103967
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| HDAC8; HDAC2; | |
| PKM; ALOX12; | |
| PTGS1; PTGS2; TYR; | |
| HTT; NPC1; THPO; RAB9A; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Histone deacetylase | HDAC8 | Histone deacetylase 8 | Q9BY41 | CHEMBL3192 |
| Histone deacetylase | HDAC2 | Histone deacetylase 2 | Q92769 | CHEMBL1937 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.431E-11 | 1.245E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.748E-10 | 4.228E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.241E-10 | 1.495E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.945E-09 | 7.178E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.306E-09 | 9.358E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.035E-08 | 1.187E-05 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.895E-08 | 1.719E-05 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 1.536E-04 | CYP1A2, CYP2C19, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.019E-06 | 6.337E-04 | PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.078E-06 | 6.522E-04 | CYP1A1, CYP1B1, HDAC2, HDAC8, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 9.507E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 1.811E-06 | 1.011E-03 | CYP1A1, CYP1A2, CYP1B1, HDAC2, HTT, LMNA, PKM, PTGS2, SMN1, SMN2, THPO, TSHR, TYR |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.955E-06 | 1.039E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1, PTGS2, RAB9A |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 2.443E-06 | 1.237E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, HTT, LMNA, NPC1, PTGS1, PTGS2, RAB9A, TYR |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.054E-06 | 1.446E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.283E-06 | 2.256E-03 | CYP1A1, CYP1A2, CYP1B1, HDAC2, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 2.416E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 2.416E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.017E-05 | 3.514E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.524E-05 | 5.028E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.132E-05 | 6.828E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.841E-05 | 8.838E-03 | CYP1A1, CYP1A2 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 6.681E-05 | 1.672E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 7.890E-05 | 1.847E-02 | SMN1, SMN2 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 8.656E-05 | 1.963E-02 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, HDAC2, HDAC8, HTT, LMNA, NPC1, PKM, PTGS1, PTGS2, RAB9A, SMN1, SMN2, TYR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.460E-10 | 8.759E-09 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.907E-07 | 7.815E-06 | ALOX12, CYP2C19, PTGS2, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.979E-07 | 7.815E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.176E-06 | 1.411E-05 | PKM, CYP1A2, CYP1A1, ALOX12, PTGS2, CYP2C19, CYP3A4, TYR, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.570E-07 | 1.136E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.213E-06 | 3.611E-05 | ALOX12, CYP2C19, PTGS2, PTGS1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.252E-06 | 6.189E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.627E-05 | 1.084E-04 | CYP1A1, CYP1B1, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.073E-06 | 3.073E-05 | CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.292E-05 | 1.375E-04 | PTGS2, TSHR, PTGS1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.590E-05 | 1.958E-04 | CYP1A2, CYP1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.296E-05 | 2.148E-04 | CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.064E-03 | 4.909E-03 | HDAC2, PKM, HDAC8 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | HDAC2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; HDAC8; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
